	US 12,214,015 B2
	Use of c-type natriuretic peptide variants to treat osteoarthritis
Charles A. O'Neill, Novato, CA (US); Todd M. Oppeneer, Novato, CA (US); and Jason K. Pinkstaff, Novato, CA (US)
Assigned to BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed by BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed on Dec. 3, 2021, as Appl. No. 17/541,992.
Application 17/541,992 is a continuation of application No. 15/779,049, granted, now 11,202,819, previously published as PCT/US2016/065520, filed on Dec. 8, 2016.
Claims priority of provisional application 62/264,682, filed on Dec. 8, 2015.
Prior Publication US 2022/0160836 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/22 (2006.01); A61K 9/19 (2006.01); A61K 31/573 (2006.01); A61K 31/728 (2006.01); A61P 19/02 (2006.01); C07K 14/58 (2006.01)

CPC A61K 38/22 (2013.01) [A61K 9/19 (2013.01); A61K 31/573 (2013.01); A61K 31/728 (2013.01); A61K 38/2242 (2013.01); A61P 19/02 (2018.01); C07K 14/58 (2013.01)]

18 Claims

1. A method of treating osteoarthritis in a subject, comprising intraarticularly administering a composition comprising a C-type natriuretic peptide (CNP) variant to the subject at a dose of from 5 μg/kg to 800 μg/kg of the CNP variant, wherein the CNP variant is selected from the group consisting of:

	(SEQ ID NO: 1)
	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
	(Pro-Gly-CNP37);

	(SEQ ID NO: 2)
	GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
	(Gly-CNP37);

	(SEQ ID NO: 43)
	QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
	[CNP-37(M32N)]

	(SEQ ID NO: 44)
	PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
	(Pro-CNP37);

	(SEQ ID NO: 45)
	MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
	(Met-CNP37);

	(SEQ ID NO: 46)
	GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
	[Gly-CN P-37(M32N)]; and

	(SEQ ID NO: 47)
	MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
	(Met-Gly-CNP37).